Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates
mSphere · 2024
DOI: 10.1128/msphere.00335-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, 2024. Verfasst von Cristian V Crisan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Stenotrophomonas maltophilia, Gram-Negative Bacterial Infections, Pseudomonas aeruginosa. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH), NIAID NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Over 160,000 people worldwide suffer from cystic fibrosis (CF), a genetic condition that causes mucus to accumulate in internal organs. Lung decline is a significant health burden for people with CF (pwCF), and chronic bacterial pulmonary infections are a major cause of death. Stenotrophomonas maltophilia complex (Smc) is an emerging, multidrug-resistant CF pathogen that can cause pulmonary exacerbations and result in higher mortality. However, little is known about the antagonistic interactions that occur between Smc isolates from pwCF and competitor bacteria. We obtained 13 Smc isolates from adult and pediatric pwCF located in the United States or Australia. We co-cultured these isolates with Pseudomonas aeruginosa , Staphylococcus aureus, and Escherichia coli . We also performed whole-genome sequencing of these Smc isolates and compared their genomes using average nucleotide identity analyses. We observed that some Smc CF isolates can engage in antagonistic interactions with P. aeruginosa and S. aureus but recovered a substantial number of P. aeruginosa and S. aureus cells following co-cultures with all tested Smc isolates. By contrast, we discovered that most Smc CF isolates display strong antibacterial properties against E. coli cells and reduce recovery below detectable limits. Finally, we demonstrate that Smc CF strains from this study belong to diverse phylogenetic lineages. IMPORTANCE Antagonism toward competitor bacteria may be important for the survival of Stenotrophomonas maltophilia complex (Smc) in external environments, for the elimination of commensal species and colonization of upper respiratory tracts to enable early infections, and for competition against other pathogens after establishing chronic infections. These intermicrobial interactions could facilitate the acquisition of Smc by people with cystic fibrosis from environmental or nosocomial sources. Elucidating the mechanisms used by Smc to eliminate other bacteria could lead to new insights into the development of novel treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.
- Emory+Children's Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Biology, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Cristian V Crisan, Morgan L Pettis, Joanna B Goldberg
Förderung
- HHS | National Institutes of Health (NIH)
- NIAID NIH HHS
- Cystic Fibrosis Foundation
Zitieren
APA
Crisan, C. V., Pettis, M. L., & Goldberg, J. B. (2024). Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates. mSphere. https://doi.org/10.1128/msphere.00335-24
Vancouver
Crisan CV, Pettis ML, Goldberg JB. Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates. mSphere. 2024. doi:10.1128/msphere.00335-24
BibTeX
@article{Crisan2024,
author = {Crisan, Cristian V and Pettis, Morgan L and Goldberg, Joanna B},
title = {Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates},
journal = {mSphere},
year = {2024},
doi = {10.1128/msphere.00335-24}
}
EUVIMED